Bevacizumab binds and inactivates all isoforms of VEGF, and works as an anti‐angiogenic agent.1 The results of phase III studies regarding the combination of BEV and cytotoxic drugs against some cancers show improvement in progression‐free survival and/or overall survival in patients with advanced cancers in first‐line and/or second line settings, including metastatic colorectal cancer, advanced non‐squamous non‐small cell lung cancer, metastatic breast cancer, renal cell carcinoma, and epithelial ovarian cancer.2 Here, VEGFA is linked to cancer.